Score Overview
Explore the 2021 public Archive ranking →
Where Innate Pharma has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IPHA does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 1.50 | — |
1 Year2025-10-23 | $ 2.19 | -31.51% |
5 Years2021-10-22 | $ 5.59 | -73.17% |
All Time2019-10-17 | $ 6.05 | -75.21% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | All Time2019-10-17 |
|---|---|---|---|---|
| Price | $ 1.50 | $ 2.19 | $ 5.59 | $ 6.05 |
| Return | — | -31.51% | -73.17% | -75.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in EUR
| Year | |||
|---|---|---|---|
| TTM | € 990K | -€ 101M | € 34M |
| 2025 | € 2M | -€ 47M | € 34M |
| 2024 | € 12M | -€ 49M | € 80M |
| 2023 | € 51M | -€ 7M | € 92M |
| 2022 | € 57M | -€ 58M | € 101M |
| 2021 | € 12M | -€ 52M | € 119M |
| 2020 | € 69M | -€ 63M | € 151M |
| IPO2019 | € 68M | -€ 20M | € 218M |
Innate Pharma fundamental performance
Between 2020 and 2025, revenue declined from € 69M to € 2M and net income went from -€ 63M to -€ 47M. Revenue increased in 1 of those 5 years; net income in 2.
Innate Pharma currently holds a 5-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.
Membership
Explore IPHA with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
